Page last updated: 2024-10-27

gabapentin and Chronic Kidney Diseases

gabapentin has been researched along with Chronic Kidney Diseases in 16 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
" Treatment with 6% topical gabapentin resulted in significantly decreased mean pruritus scores at 1 week (mean score 2."9.34A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus. ( Aquino, TMO; Luchangco, KAC; Sanchez, EV; Verallo-Rowell, VM, 2020)
"Gabapentin relieved itching in 47 patients (66%)."9.16Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012)
"To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD."7.81Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015)
" Treatment with 6% topical gabapentin resulted in significantly decreased mean pruritus scores at 1 week (mean score 2."5.34A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus. ( Aquino, TMO; Luchangco, KAC; Sanchez, EV; Verallo-Rowell, VM, 2020)
"Gabapentin relieved itching in 47 patients (66%)."5.16Uraemic pruritus: relief of itching by gabapentin and pregabalin. ( Baharani, J; Dasgupta, I; Rayner, H; Smith, S; Suresh, V, 2012)
" In the meantime, gabapentin appears to be the most evidence-based widely available uremic pruritus treatment, as long as care is taken with dosing and monitoring of side-effects."5.05Recent advances in the treatment of uremic pruritus. ( Collister, D; Rigatto, C; Trachtenberg, AJ, 2020)
"Despite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak."4.95Treatment of Uremic Pruritus: A Systematic Review. ( Askin, N; Bohm, C; Komenda, P; Lerner, B; Rigatto, C; Shaw, J; Simonsen, E; Tangri, N, 2017)
"To determine the safety and effectiveness of gabapentin for pruritus or RLS in conservatively managed patients (n = 34) with CKD and ESKD."3.81Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease. ( Brennan, F; Brown, MA; Cheikh Hassan, HI; Collett, G; Josland, EA, 2015)
"Mycophenolic acid was detected in all cats."2.61 ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019)
" To inform their safe prescribing in older adults with chronic kidney disease (CKD), we examined the 30-day risk of serious adverse events according to the prescribed starting dose."1.72Higher-Dose Gabapentinoids and the Risk of Adverse Events in Older Adults With CKD: A Population-Based Cohort Study. ( Ahmadi, F; Blake, PG; Cowan, A; Fleet, JL; Garg, AX; Muanda, FT; Sontrop, JM; Weir, MA, 2022)
" This study evaluated GP prescribing patterns and whether excessive dosing was associated with increased incidence of gabapentinoid-related adverse events (GRAEs)."1.72Gabapentinoid dosing and adverse events in patients with chronic kidney disease. ( Cave, B; Hudson, JQ; Washington, K; Wells, DA; Zhu, R, 2022)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (62.50)24.3611
2020's6 (37.50)2.80

Authors

AuthorsStudies
Muanda, FT1
Weir, MA1
Ahmadi, F1
Sontrop, JM1
Cowan, A1
Fleet, JL1
Blake, PG1
Garg, AX1
Wells, DA1
Washington, K1
Cave, B1
Zhu, R1
Hudson, JQ1
Safarpour, Y1
Vaziri, ND1
Jabbari, B1
Bobenko, AI1
Heller, S1
Schmitt, N1
Cherdtrakulkiat, R1
Lawung, R1
Nabu, S1
Tantimavanich, S1
Sinthupoom, N1
Prachayasittikul, S1
Prachayasittikul, V1
Zhang, B1
Wu, C1
Zhang, Z2
Yan, K1
Li, C2
Li, Y4
Li, L3
Zheng, C1
Xiao, Y1
He, D1
Zhao, F1
Su, JF1
Lun, SM1
Hou, YJ1
Duan, LJ1
Wang, NC1
Shen, FF1
Zhang, YW1
Gao, ZW1
Li, J5
Du, XJ1
Zhou, FY1
Yin, Z1
Zhu, J2
Yan, D1
Lou, H1
Yu, H1
Feng, C1
Wang, Z1
Wang, Y4
Hu, X1
Li, Z2
Shen, Y1
Hu, D1
Chen, H1
Wu, X1
Duan, Y1
Zhi, D1
Zou, M2
Zhao, Z1
Zhang, X2
Yang, X2
Zhang, J2
Wang, H1
Popović, KJ1
Popović, DJ1
Miljković, D1
Lalošević, D1
Čapo, I1
Popović, JK1
Liu, M1
Song, H2
Xing, Z1
Lu, G1
Chen, D1
Valentini, AM1
Di Pinto, F1
Coletta, S1
Guerra, V1
Armentano, R1
Caruso, ML1
Gong, J1
Wang, N1
Bian, L1
Wang, M1
Ye, M1
Wen, N1
Fu, M1
Fan, W1
Meng, Y1
Dong, G1
Lin, XH1
Liu, HH1
Gao, DM1
Cui, JF1
Ren, ZG1
Chen, RX1
Önal, B1
Özen, D1
Demir, B1
Akkan, AG1
Özyazgan, S1
Payette, G1
Geoffroy, V1
Martineau, C1
Villemur, R1
Jameel, T1
Baig, M1
Gazzaz, ZJ1
Tashkandi, JM1
Al Alhareth, NS1
Khan, SA1
Butt, NS1
Wang, J2
Geng, Y1
Zhang, Y3
Wang, X2
Liu, J2
Basit, A1
Miao, T1
Liu, W1
Jiang, W1
Yu, ZY1
Wu, L2
Qu, B1
Sun, JX1
Cai, AL1
Xie, LM1
Groeneveld, J1
Ho, SL1
Mackensen, A1
Mohtadi, M1
Laepple, T1
Genovesi, S1
Nava, E1
Bartolucci, C1
Severi, S1
Vincenti, A1
Contaldo, G1
Bigatti, G1
Ciurlino, D1
Bertoli, SV1
Slovak, JE1
Hwang, JK1
Rivera, SM1
Villarino, NF1
Li, S1
Cao, G1
Ling, M1
Ji, J1
Zhao, D1
Sha, Y1
Gao, X1
Liang, C2
Guo, Q1
Zhou, C1
Ma, Z1
Xu, J1
Wang, C1
Zhao, W1
Xia, X1
Jiang, Y1
Peng, J1
Jia, Z1
Li, F1
Chen, X2
Mo, J1
Zhang, S2
Li, X1
Huang, T1
Zhu, Q1
Wang, S1
Ge, RS1
Fortunato, G1
Lin, J2
Agarwal, PK1
Kohen, A1
Singh, P1
Cheatum, CM1
Zhu, D1
Hayman, A1
Kebede, B1
Stewart, I1
Chen, G1
Frew, R1
Guo, X1
Gong, Q1
Borowiec, J1
Han, S1
Zhang, M1
Willis, M1
Kreouzis, T1
Yu, K1
Chirvony, VS1
Sekerbayev, KS1
Pérez-Del-Rey, D1
Martínez-Pastor, JP1
Palazon, F1
Boix, PP1
Taurbayev, TI1
Sessolo, M1
Bolink, HJ1
Lu, M1
Lan, Y1
Xiao, J1
Song, M1
Chen, C1
Huang, Q1
Cao, Y1
Ho, CT1
Qi, B1
Wang, Q1
Zhang, W1
Fang, L1
Xie, CL1
Chen, R1
Yang, S1
Xia, JM1
Zhang, GY1
Chen, CH1
Yang, XW1
Domenech-Ximenos, B1
Garza, MS1
Prat-González, S1
Sepúlveda-Martínez, Á1
Crispi, F1
Perea, RJ1
Garcia-Alvarez, A1
Sitges, M1
Kalumpha, M1
Guyo, U1
Zinyama, NP1
Vakira, FM1
Nyamunda, BC1
Varga, M1
Drácz, L1
Kolbenheyer, E1
Varga, F1
Patai, ÁV1
Solymosi, N1
Patai, Á1
Kiss, J1
Gaál, V1
Nyul, Z1
Mosdósi, B1
Valdez, M1
Moosavi, L1
Heidari, A1
Novakovic-Agopian, T1
Kornblith, E1
Abrams, G1
McQuaid, JR1
Posecion, L1
Burciaga, J1
D'Esposito, M1
Chen, AJW1
Samy El Gendy, NM1
Wesolowska, P1
Georg, D1
Lechner, W1
Kazantsev, P1
Bokulic, T1
Tedgren, AC1
Adolfsson, E1
Campos, AM1
Alves, VGL1
Suming, L1
Hao, W1
Ekendahl, D1
Koniarova, I1
Bulski, W1
Chelminski, K1
Samper, JLA1
Vinatha, SP1
Rakshit, S1
Siri, S1
Tomsejm, M1
Tenhunen, M1
Povall, J1
Kry, SF1
Followill, DS1
Thwaites, DI1
Izewska, J1
Kang, JH1
Yoon, Y1
Song, J1
Van de Winckel, A1
Gauthier, L1
Chao, CT1
Lee, YH1
Li, CM1
Han, DS1
Huang, JW1
Huang, KC1
Ni, L1
Güttinger, R1
Triana, CA1
Spingler, B1
Baldridge, KK1
Patzke, GR1
Shen, X1
Wang, B1
Xie, S1
Deng, W1
Wu, D1
Zhang, Q1
Voskamp, BJ1
Peelen, MJCS1
Ravelli, ACJ1
van der Lee, R1
Mol, BWJ1
Pajkrt, E1
Ganzevoort, W1
Kazemier, BM1
Tibrewala, R1
Bahroos, E1
Mehrabian, H1
Foreman, SC1
Link, TM1
Pedoia, V1
Majumdar, S1
Jablonski, CL1
Leonard, C1
Salo, P1
Krawetz, RJ1
Yoon, N1
Hong, SN1
Cho, JG1
Jeong, HK1
Lee, KH1
Park, HW1
Barman, S1
Konai, MM1
Samaddar, S1
Haldar, J1
Mohamed, HSH1
Li, CF1
Hu, ZY1
Deng, Z1
Chen, LH1
Su, BL1
Chu, K1
Liu, YP1
Li, YB1
Zhang, H1
Xu, C1
Zou, Z1
Wu, Z1
Xia, Y1
Zhao, P1
Wang, HT1
de Biase, S1
Pellitteri, G1
Gigli, GL1
Valente, M1
Aquino, TMO1
Luchangco, KAC1
Sanchez, EV1
Verallo-Rowell, VM1
Trachtenberg, AJ1
Collister, D1
Rigatto, C2
Duggal, V1
Thomas, IC1
Montez-Rath, ME1
Chertow, GM1
Kurella Tamura, M1
Simonsen, E1
Komenda, P1
Lerner, B1
Askin, N1
Bohm, C1
Shaw, J1
Tangri, N1
Sinclair, PM1
Ishida, JH1
McCulloch, CE1
Steinman, MA1
Grimes, BA1
Johansen, KL1
Novick, TK1
Surapaneni, A1
Shin, JI1
Ballew, SH1
Alexander, GC1
Inker, LA1
Chang, AR1
Grams, ME1
Sriperumbuduri, S1
Hiremath, S1
Rayner, H1
Baharani, J1
Smith, S1
Suresh, V1
Dasgupta, I1
Mettang, T1
Kremer, AE1
Cheikh Hassan, HI1
Brennan, F1
Collett, G1
Josland, EA1
Brown, MA1
Gopaluni, S1
Sherif, M1
Ahmadouk, NA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750]Early Phase 160 participants (Anticipated)Interventional2020-12-01Not yet recruiting
Prospective Randomized Study Evaluating the Efficacy of the Spherical Absorptive Carbon AST-120 in Hemodialysis Patients With Uremic Pruritus..[NCT04639674]Phase 4100 participants (Actual)Interventional2020-07-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

8 reviews available for gabapentin and Chronic Kidney Diseases

ArticleYear
Restless Legs Syndrome in Chronic Kidney Disease- a Systematic Review.
    Tremor and other hyperkinetic movements (New York, N.Y.), 2023, Volume: 13

    Topics: Child; Dopamine Agents; Gabapentin; Humans; Iron; Pregabalin; Quality of Life; Renal Insufficiency,

2023
    Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227

    Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P

2019
Recent advances in the treatment of uremic pruritus.
    Current opinion in nephrology and hypertension, 2020, Volume: 29, Issue:5

    Topics: Gabapentin; Humans; Piperidines; Pruritus; Renal Dialysis; Renal Insufficiency, Chronic

2020
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Treatment of Uremic Pruritus: A Systematic Review.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:5

    Topics: Administration, Cutaneous; Amines; Analgesics; Anti-Asthmatic Agents; Antipruritics; Capsaicin; Crom

2017
Interventions for chronic kidney disease-associated restless legs syndrome.
    International journal of evidence-based healthcare, 2018, Volume: 16, Issue:3

    Topics: Exercise Therapy; Gabapentin; Humans; Indoles; Iron-Dextran Complex; Levodopa; Randomized Controlled

2018
The case for cautious consumption: NSAIDs in chronic kidney disease.
    Current opinion in nephrology and hypertension, 2019, Volume: 28, Issue:2

    Topics: Acute Kidney Injury; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Cost-Ben

2019
Uremic pruritus.
    Kidney international, 2015, Volume: 87, Issue:4

    Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxyl

2015
Interventions for chronic kidney disease-associated restless legs syndrome.
    The Cochrane database of systematic reviews, 2016, 11-07, Volume: 11

    Topics: Amines; Anticonvulsants; Ascorbic Acid; Cyclohexanecarboxylic Acids; Dopamine Agonists; Exercise The

2016

Trials

2 trials available for gabapentin and Chronic Kidney Diseases

ArticleYear
A randomized controlled study of 6% gabapentin topical formulation for chronic kidney disease-associated pruritus.
    International journal of dermatology, 2020, Volume: 59, Issue:8

    Topics: Double-Blind Method; Gabapentin; Humans; Pruritus; Renal Dialysis; Renal Insufficiency, Chronic; Tre

2020
Uraemic pruritus: relief of itching by gabapentin and pregabalin.
    Nephron. Clinical practice, 2012, Volume: 122, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Comorbidity; Cyclohexanecarboxylic Acids; Dose-R

2012

Other Studies

6 other studies available for gabapentin and Chronic Kidney Diseases

ArticleYear
Higher-Dose Gabapentinoids and the Risk of Adverse Events in Older Adults With CKD: A Population-Based Cohort Study.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022, Volume: 80, Issue:1

    Topics: Aged; Aged, 80 and over; Brain Diseases; Cohort Studies; Female; Gabapentin; Humans; Male; Ontario;

2022
Gabapentinoid dosing and adverse events in patients with chronic kidney disease.
    Clinical nephrology, 2022, Volume: 98, Issue:3

    Topics: Adult; Aged; Antipsychotic Agents; Female; Gabapentin; Humans; Kidney Failure, Chronic; Male; Middle

2022
National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race.
    Journal of the American Society of Nephrology : JASN, 2021, 06-01, Volume: 32, Issue:6

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Bac

2021
Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.
    Journal of the American Society of Nephrology : JASN, 2018, Volume: 29, Issue:7

    Topics: Accidental Falls; Aged; Analgesics; Emergency Service, Hospital; Female; Fractures, Bone; Gabapentin

2018
Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD.
    Clinical journal of the American Society of Nephrology : CJASN, 2018, 12-07, Volume: 13, Issue:12

    Topics: Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Drug Utilization; Female; G

2018
Efficacy and safety of gabapentin for uremic pruritus and restless legs syndrome in conservatively managed patients with chronic kidney disease.
    Journal of pain and symptom management, 2015, Volume: 49, Issue:4

    Topics: Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-

2015